Effect of glutamine on change in early postoperative intestinal permeability and its relation to systemic inflammatory response

Zhu-Fu Quan, Chong Yang, Ning Li, Jie-Shou Li

INTRODUCTION

Gut has been considered as one of the central organs responding to stresses in surgical patients[1]. In the last few years, animal experiments and clinical researches have proved that the intestinal permeability increases during stresses, such as severe trauma, operation. Glutamine as a semi-essential amino acid is a special nutrient to intestinal mucosal cells. It can reduce the permeability of gut, but becomes increasingly exhausted after severe trauma or operation. In this research we studied the effects of glutamine on the change of intestinal permeability and its relationship to systemic inflammatory response in abdominal postoperative patients.

AIM: To study the effects of glutamine (Gln) on the change of intestinal permeability and its relationship to systemic inflammatory response in early abdominal postoperative patients.

RESULTS: The patients in the 2 groups were comparable prior to drug administration. Serum Gln concentration was significantly decreased in the placebo group and increased in the Gln group 7 d after drug administration. Urine L/M ratio was significantly increased in the placebo group and decreased in the Gln group. The serum concentration of endotoxin, diamine oxidase and malondialdehyde was significantly decreased in the Gln group compared with those in the placebo group. Temperatures, heart rates and WBC counts were significantly lower in the Gln group than those in the placebo group.

CONCLUSION: Gut is one of the sources of systemic inflammatory response in abdominal postoperative patients and glutamine can decrease intestinal permeability, maintain intestinal barrier and attenuate systemic inflammatory response in early postoperative patients.

MATERIALS AND METHODS

Patient grouping

A prospective, randomized, double-blind and controlled trial was taken. Twenty abdominal surgical patients aged 18-65 years and without any severe disease in liver, kidney, cardiovascular system and hematopoietic system, were randomized into Gln group (oral administration of glutamine, 30 g/d, for 7 d, n=10) and placebo group (oral administration of placebo, 30 g/d, for 7 d, n=10). Their sex, age, body mass and operation type were similar (Tables 1, 2).

Drug dose and administration

Glutamine was dissolved in warm water (1 g in 10 mL) and orally taken or by gastric tube (10 g one time, and 3 times per day) after operation for 7 d. Placebo was administered as glutamine.

Measurement

Temperature and heart rate of all patients were daily recorded. White blood cell counts(WBC) and biochemical variables were measured before operation and 4 and 7 d after drug administration. Serum concentrations of glutamine, endotoxin, diamine oxidase and malondialdehyde and urine lactulose/mannito (L/M) ratio were measured before and 7 d after drug administration.

Statistical method

Results were expressed as mean±SD and analyzed with Student t-test. P<0.05 was considered statistically significant.
RESULTS

General condition
During the research, there were no complication and death in both Gln group and placebo group.

Temperature
The highest, average and lowest temperatures increased after operation. The highest and average temperatures from d 3 to 6 and the lowest temperatures from d 2 to 6 in the Gln group were significantly lower than those in the placebo group.

Heart rate
The highest, average and lowest heart rates increased after operation in patients of both groups. The highest and average heart rates on d 2, 3 and 5 and the lowest heart rates from d 2 to 5 were significantly lower in the Gln group than in the placebo group.

WBC count
WBC counts increased from the first day after operation in both groups with the maximum being above 12.0×10^9/L. WBC counts decreased to normal level 4 d later in the Gln group, whereas in the placebo group the WBC counts decreased to normal level 7 d later in the placebo group.

Serum concentration of Gln
In the placebo group, the serum concentration of Gln decreased from 432.17±142.68 µmol/L to 250.78±77.10 µmol/L (P<0.05), whereas in the Gln group the serum concentration of Gln increased from 361.17±161.25 µmol/L to 583.22±171.52 µmol/L (P<0.05). The serum concentration of Gln in the Gln group was significantly higher than that in the placebo group (P<0.01) (Table 3).

Table 3  Serum levels of Gln in two groups (µmol/ L)

| Group  | Case(n) | Sex | Age(yr) | Diagnosis                     | Operation type          |
|--------|---------|-----|---------|-------------------------------|-------------------------|
| Placebo group | 1       | Male | 55      | Cardiac orifice cancer        | Total gastrectomy       |
|         | 2       | Male | 30      | Acute suppurative cholangitis | Choledectomy choledochotomy |
|         | 3       | Female | 40    | Rectal cancer                 | Anterior resection of rectum |
|         | 4       | Male | 47      | Sigmoid cancer                | Sigmoidectomy           |
|         | 5       | Male | 62      | Cardiac orifice cancer        | Proximal subtotal gastrectomy |
|         | 6       | Female | 28    | Rectal cancer                 | Anterior resection of rectum |
|         | 7       | Female | 52    | Cholecystolithiasis           | Cholecystectomy         |
|         | 8       | Male | 49      | Gastric cancer                | Subtotal gastrectomy    |
|         | 9       | Male | 60      | Gastric cancer                | Subtotal gastrectomy    |
|         | 10      | Male | 60      | Cardiac orifice cancer        | Proximal subtotal gastrectomy |
| Gln group | 1       | Male | 55      | Pancreas pseudocyst           | Cyst-jejunal Roux-en-Y anastomosis |
|         | 2       | Female | 56    | Ascending colon cancer        | Right semi-colectomy    |
|         | 3       | Female | 60    | Rectal cancer                 | Anterior resection of rectum |
|         | 4       | Female | 54    | Sigmoid cancer                | Sigmoidectomy           |
|         | 5       | Male | 48      | Cardiac orifice cancer        | Proximal subtotal gastrectomy |
|         | 6       | Male | 43      | Ascending colon cancer        | Right semi-colectomy    |
|         | 7       | Male | 64      | Gastric cancer                | Proximal subtotal gastrectomy |
|         | 8       | Female | 29    | Gastric cancer                | Proximal subtotal gastrectomy |
|         | 9       | Male | 43      | Sigmoid cancer                | Sigmoidectomy           |
|         | 10      | Male | 36      | Acute biliary pancreatitis    | Selective cholecystectomy |

Table 4  Serum DAO levels in two groups (U/ mL)

| Group  | Before drug administration | 7 d after drug administration |
|--------|----------------------------|-------------------------------|
| Placebo group | 2.06±0.48  | 3.18±1.13                   |
| Gln group   | 2.26±0.63   | 1.25±0.63                   |

P<0.01 vs before administration; P<0.01 vs placebo group.

Serum MDA concentration
Serum MDA concentrations were not significantly different in the 2 groups before drug administration. Seven days after drug administration, they increased in the placebo group and decreased in the Gln group (P<0.01). The serum MDA concentrations were significantly different between the two groups (P<0.01) after drug administration (Table 5).

Table 5  Serum MDA levels in two groups (nmol/ mL)

| Group  | Before drug administration | 7 d after drug administration |
|--------|----------------------------|-------------------------------|
| Placebo group | 3.94±0.56    | 4.85±0.63                   |
| Gln group   | 4.46±0.67    | 3.53±0.59                   |

P<0.01 vs before drug administration; P<0.01 vs placebo group.

Serum endotoxin concentration
Levels of serum endotoxin in the 2 groups were not significantly different before drug administration. After 7 d, the serum endotoxin concentrations increased in the placebo group significantly and decreased in the Gln group (P<0.05) with a very significant difference between the two groups (P<0.01, Table 6).

Table 6  Levels of serum endotoxin in two groups (EU/ mL)

| Group  | Before drug administration | 7 d after drug administration |
|--------|----------------------------|-------------------------------|
| Placebo group | 0.21±0.07    | 0.25±0.08                   |
| Gln group   | 0.23±0.05    | 0.18±0.06                   |

P<0.05 vs before drug administration; P<0.01 vs placebo group.
The ratio of L/M was not significantly different in the 2 groups initially, which was 134.00±18.48 in the placebo group and 146.10±20.21 in the Gln group. After 7 d, the ratio of L/M significantly increased in the placebo group (P<0.01), and significantly decreased in the Gln group (P<0.05). Then, the ratio of L/M was significantly lower in the Gln group than in the placebo group (P<0.01, Table 7).

Table 7 Changes of urine L/M ratio in two groups

| Group | Before drug administration | 7 d after drug administration |
|-------|---------------------------|-------------------------------|
| Placebo group | 134.00±18.48 | 194.83±51.31* |
| Gln group | 146.10±20.21 | 117.47±25.68* |

*P<0.05, **P<0.01, vs before drug administration; †P<0.01 vs placebo group.

DISCUSSION

Normally, besides digestion and absorption, the gut functions as a mucosal barrier to bacteria, endotoxin and some other toxins. Whether the mucosal barrier works well or not is closely related to intestinal permeability. To measure it, some material with large molecular weight was used as a probe. Lactulose/mannito was most often used[7]. During the period of severe trauma or operation, the intestinal mucosal barrier was damaged, and therefore the intestinal permeability increased from which bacteria and endotoxin can easily transfer through the intestinal mucosa and invade tissue and blood, which is called bacterial translocation. Then the bacteria and endotoxin in blood would inversely affect the intestinal mucosal barrier and get it further damaged, thus forming a vicious circle. The more critical condition was that systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) could even occur[11]. Therefore, how to maintain the function of intestinal mucosal barrier in severe trauma or postoperative patients and how to decrease the permeability and bacterial translocation to avoid the occurrence of SIRS and MODS have become a very important problem.

Brooks et al.[9] took L/M as a molecular probe to measure the intestinal permeability in 25 cases of gastrointestinal tumor. The ratio of L/M was greatly increased in the placebo group. Li et al.[10] measured 24 hours’ urine 45Ca-DTPA taken orally in 8 cases of postoperative patients 7 d after operation. The excretory rate of 45Ca-DTPA was 13.71±4.85%, which almost doubled to that before operation (6.64±3.95%). In this research, serum Gln concentration decreased by 41.97%, and increased by 61.48% in the Gln group after administration of Gln for 7 d, when compared with the level before administration. It was significantly higher in the Gln group than in the placebo group. The ratio of L/M was not significantly different in the two groups initially. After 7 d, the ratio of L/M significantly increased in the control group and significantly decreased in the Gln group. The ratio of L/M was significantly lower in the Gln group than in the placebo group. This result showed that supplement of entocenetic Gln could significantly decrease the intestinal permeability. Jiang et al.[11,12] also proved this in surgical patients. Supplement of alanyl-glutamine could increase serum Gln level and decrease urine L/M ratio.

Li et al.[13,14] studied that measurement of serum DAO was helpful to determine the degree of intestinal mucous damage. In their research after administration of Gln, serum DAO level significantly increased in the placebo group and significantly decreased in the Gln group compared with the level before drug administration. The change in serum endotoxin level was similar in the 2 groups. This change of serum endotoxin level was related to the fact that high serum Gln level could enhance the function of intestinal mucosal barrier. Low serum endotoxin level was helpful to reduce SIRS in patients. Some researchers showed that endotoxin in early trauma could lead to the increase of production and release of cytokines such as TNF-α, IL-6, IL-8, which could take part in the generation of SIRS[17].

Haga et al.[18] studied the postoperative conditions of 292 gastrointestinal patients. The result was that 245 patients had SIRS early after operation, which was 83.9%. The possibility of postoperative complication and MODS in these patients was much higher than that in those without SIRS. The results in our study indicate that SIRS can be reduced in early postoperative patients.

REFERENCES

1. Wilmore DW, Smith RJ, O’Dwyer ST, Jacobs DO, Ziegler TR, Wang XD. The gut: a central organ after surgical stress. Surgery 1988; 104: 917-923
2. You ZY, Yu B, Lei ZH, Zhao Y. The determination of Gln and Gln in plasma and tissue by RP-HPLC. Disan Junyi Da xue xue bao 1995; 17: 152-153
3. Hosoda N, Nishi M, Nakagawa M, Hiramatsu Y, Hioki K, Yamanoto M. Structural and functional alterations in the gut of parenterally or enterally fed rats. J Surg Res 1989; 47: 129-133
4. Zhang JX, Gao SG. Malondialdehyde kit for determining serum lipoperoxide. Nanjing Tiedao Xue yu xue bao 1997; 16: 63-64
5. Behrens RH, Docherty H, Elia M, Neale G. A simple enzymatic method for the assay of urinary lactulose. Clin Chim Acta 1984; 137: 361-367
6. Lunn PG, Northrop CA, Northop AJ. Automated enzymatic assays for the determination of intestinal permeability probes in urine. 2. Mannitol. Clin Chim Acta 1989; 183: 163-170
7. Bjarnason I, MacPherson A, Hollandar D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566-1581
8. Saadla R, Schein M, MacFarlane C, Boffard KD. Gut barrier function and the surgeon. Br J Surg 1990; 77: 487-492
9. Brooks AD, Hochwald SN, Heslin MJ, Harrison LE, Burt M, Brennan MF. Intestinal permeability after early postoperative enteral nutrition in patients with upper gastrointestinal malignancy. JPN 1999; 23: 75-79
10. Li N, Liu FN, Li YS, Kang J, Li FJ, Li JS. The changes of plasma glutamine and its influence on intestinal permeability after abdominal surgery. Changwai Yu Chaogai Yingyang 1998; 5: 3-6
11. Jiang ZM, Wang LJ, Qi Y, Liu TH, Qiu MR, Yang NF, Wilmore DW. Comparison of parenteral nutrition supplemented with L-glutamine or glutamine dipeptides. JPN 1999, 17: 134-141
12. Bai MX, Jiang ZM, Liu YM, Wang WT, Li DM, Wilmore DW. Effects of alanyl-glutamine on gut barrier function. Nutrition 1996; 12: 793-796
13. Li JY, Lu Y, Xue LB. The effect of oral administration of glutamine on free amino acids concentration in the plasma of scalded rat. Anji suan He Shengwuziyuan 2000; 22: 51-56
14. Lu Y, Li JY, Sun SR, Jin H, Jiang XG, Sun XQ, Sheng ZY. Relationship between change of plasma diamine oxidase activity and gut injury in rats during gut ischemia-reperfusion. Anji suan He Shengwuziyuan 2000; 22: 50-54
15. Li JY, Lu Y, Fu XB, Jin H, Hu S, Sun XQ, Sheng ZY. The significance of changes of diamine oxidase activity in intestinal injury after trauma. Zonghao Wu Ze zhong jing Ji Xu xue 2000; 12: 482-484
16. Li JY, Lu Y, Hao J, Jin H, Xu HJ. Determination of diamine oxidase activity in intestinal tissue and blood using spectrophotometry. Anji suan He Shengwuziyuan 1996; 18: 28-30
17. Jiang JX, Tian KL, Chen HS, Zhu PF, Wang ZG. Changes of plasma cytokines in patients with severe trauma and their relation ship with organ damage. Zhonghua Wai ke Za zhi 1997; 35: 406-407
18. Haga Y, Beppu T, Doi K, Nozawa F, Mugita N, Ike S, Ogawa M. Systemic inflammatory response syndrome and organ dysfunction following gastrointestinal surgery. Crit Care Med 1997; 25: 1994-2000

Edited by Wang XL and Xu FM